IVX-411 explained
IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2] [3] [4]
In 2022 results were released that the RDB antigen component of the vaccine was unstable, which resulted in reduced potency.[5]
Notes and References
- Web site: ANZCTR - Registration. 2021-08-18. anzctr.org.au.
- Web site: Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc.. 2021-08-18. investors.icosavax.com. en. 30 October 2021. https://web.archive.org/web/20211030145323/https://investors.icosavax.com/news-releases/news-release-details/icosavax-initiates-phase-12-trial-covid-19-vlp-vaccine-candidate/. dead.
- Web site: Two nanoparticle vaccines enter clinical trials . Institute for Protein Design. 2 June 2021. 2021-08-18. en-US.
- Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, Röltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C, Dufour J, Spencer S, Doyle-Meyers L, Bohm RP, Maness NJ, Roy C, Plante JA, Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O'Hagan DT, Van Der Most R, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S, Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport J, Suthar MS, King NP, Veesler D, Pulendran B . 6 . Adjuvanting a subunit COVID-19 vaccine to induce protective immunity . Nature . 594 . 7862 . 253–258 . June 2021 . 33873199 . 10.1038/s41586-021-03530-2 . 2021Natur.594..253A . free .
- Web site: Icosavax Announces Results from IVX-411 Drug Product Investigation and Outlines Additional Corporate Milestones . BioSpace . 28 July 2022.
